Numinus Wellness (TSE:NUMI) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Numinus Wellness Inc. has addressed the FDA’s refusal to approve MDMA-assisted therapy for PTSD by reiterating their commitment to advancing psychedelic therapies and continuing their pursuit of profitability through existing operations. Despite the setback, Numinus remains confident in the future efficacy of MDMA and other psychedelic treatments, and highlights their continued leadership in providing mental health care and conducting clinical research.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.